Skip to main content

Eczema

Immunology
9
Pipeline Programs
15
Companies
14
Clinical Trials
2 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
4
0
4
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 18 programs with unclassified modality

Immunology is a $15.0B market in mature growth, driven by blockbuster JAK inhibitors and biologics across multiple therapeutic domains.

$15.0B marketMature↑ Growing30 products15 companies

Key Trends

  • JAK inhibitors and corticosteroid combinations dominate spending (39% combined)
  • Multiple patent cliffs emerging 2026-2028, creating generic competition risk
  • Robust pipeline with 4,996 trials signals continued innovation and market expansion

Career Verdict

Strong career opportunity for those targeting Medical Affairs, Commercial, or R&D roles, with solid hiring momentum and premium salaries in specialized functions.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1MOUNJAROGrowing
$2.4B
#2SYMBICORTStable
$2.0B
AstraZeneca·LOE_APPROACHING
#3JAKAFIDeclining
$1.9B
Incyte·LOE_APPROACHING2.6yr
#4RESTASISStable
$1.5B
AbbVie·PEAK8.0yr
#5RINVOQGrowing
$976M
AbbVie·PEAK11.8yr

Drug Class Breakdown

Janus Kinase Inhibitors
$3.0B(20%)

dominant class with patent cliff risk

Corticosteroid Hormone Receptor Agonists
$2.8B(19%)

established, mature market segment

G-Protein-linked Receptor Interactions
$2.4B(16%)

driven by single blockbuster

Calcineurin Inhibitors
$1.6B(11%)

established immunosuppression class

Tumor Necrosis Factor Receptor Blocking Activity
$1.2B(8%)

legacy biologic class with competition

Career Outlook

Growing

Immunology offers a maturing but actively growing market with strong corporate investment, deep pipelines, and premium compensation across commercial and clinical functions. The therapeutic area is characterized by complex mechanism-of-action portfolios, frequent label expansion opportunities, and multi-indication blockbusters that require sophisticated Medical Affairs and Commercial expertise. Patent cliff risk on JAK inhibitors creates both disruption and opportunity for those skilled in competitive positioning and pipeline strategy.

Breaking In

Enter through Medical Affairs, Clinical Operations, or Commercial Training programs at large companies (J&J, AbbVie, Bristol Myers Squibb); a foundation in immunology mechanisms is valuable but trainable.

For Experienced Professionals

Leverage patent cliff risk to position yourself in competitive differentiation, pipeline strategy, or M&A integration roles, where demand for immunology expertise is highest.

In-Demand Skills

Medical Affairs and MSL expertise in immunosuppression and inflammatory diseasesJAK inhibitor mechanism expertise and competitive positioningClinical trial design and phase transition managementCommercial acumen for premium-priced biologics and small moleculesRegulatory strategy for label expansions and lifecycle management

Best For

Medical Science LiaisonBrand ManagerSenior Medical Affairs ManagerClinical Development ManagerCommercial Strategy Lead

Hiring Landscape

$212K-$387K

Immunology hiring totals 340 open positions with strong demand across Medical Affairs (110 roles, $257K avg), Commercial (83 roles, $270K avg), and R&D (31 roles, $387K avg). Johnson & Johnson, Bristol Myers Squibb, and AbbVie are the top recruiters, reflecting their portfolio depth and market dominance. Compensation is competitive, particularly in R&D and Clinical Operations.

340
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

45Growing
31Growing
29Stable

By Department

Medical Affairs(32%)
$257K
Commercial(24%)
$270K
Research & Development(9%)
$387K
Clinical Operations(4%)
$345K
Manufacturing(2%)
$212K

Strong hiring demand with premium compensation in Medical Affairs and Commercial roles; R&D positions command highest salaries but are less abundant.

On Market (1)

Approved therapies currently available

PANRETINApproved
alitretinoin
Unknown Company
Retinoid [EPC]topical1999
965K Part D

Competitive Landscape

14 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
3 programs
1
2
Clobetasone Butyrate 0.05% CreamPhase 3
alitretinoinPhase 3
Alclometasone dipropionate creamPhase 2
EMS
EMSBrazil - Hortolândia
2 programs
2
Group 1Phase 31 trial
polymyxin B sulphate + prednisolone + benzocaine + clioquinolPhase 31 trial
Active Trials
NCT01257061Completed310Est. Aug 2013
NCT01429701Completed76Est. Aug 2012
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
2 programs
2
Avoidance of peanutPhase 21 trial
Peanut Consumption GroupPhase 21 trial
Active Trials
NCT01366846Completed556Est. May 2015
NCT00329784Completed640Est. May 2014
Integrated Biosciences
Integrated BiosciencesCA - San Carlos
1 program
1
Furoic acid loperamide hydrochloride creamPhase 21 trial
Active Trials
NCT02517957Unknown342
GSK
GSKLONDON, United Kingdom
2 programs
Alclometasone dipropionate creamPHASE_21 trial
alitretinoinPHASE_31 trial
Active Trials
NCT02075632Completed310Est. Nov 2006
NCT00817063Completed599Est. Apr 2012
Physical Sciences
Physical SciencesMA - Andover
1 program
Cutaneous Biomarkers in Atopic Eczema Using a Non-Invasive Micro-Suction Device in BabiesN/A1 trial
Active Trials
NCT07228962Not Yet Recruiting30Est. Jun 2027
Innovation Pharmaceuticals
1 program
Moisturizing lotionN/A1 trial
Active Trials
NCT07463079Recruiting15Est. May 2026
Philips
PhilipsNetherlands - Amsterdam
1 program
PSO-CT02 deviceN/A1 trial
Active Trials
NCT02002871Completed21Est. Mar 2014
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Studies of Skin Microbes in Healthy People and in People With Skin ConditionsN/A1 trial
Active Trials
NCT00605878Recruiting530
Genome & Company
Genome & CompanyKorea - Suwon
1 program
Studies of Skin Microbes in Healthy People and in People With Skin ConditionsN/A
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
Sunflower oilN/A1 trial
Active Trials
NCT01142999Unknown46Est. Sep 2012
Zai Lab
Zai LabCA - South SF
1 program
ZL-3101PHASE_21 trial
Active Trials
NCT03134352Completed290Est. Sep 2018
Labcorp
LabcorpBURLINGTON, NC
1 program
ZL-3101PHASE_2
Regeneron
RegeneronTARRYTOWN, NY
1 program
DupilumabPHASE_4Monoclonal Antibody1 trial
Active Trials
NCT05265234Unknown15Est. Mar 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
RegeneronDupilumab
EMSGroup 1
EMSpolymyxin B sulphate + prednisolone + benzocaine + clioquinol
GSKalitretinoin
Zai LabZL-3101
Integrated BiosciencesFuroic acid loperamide hydrochloride cream
Allergy TherapeuticsAvoidance of peanut
Allergy TherapeuticsPeanut Consumption Group
GSKAlclometasone dipropionate cream
Physical SciencesCutaneous Biomarkers in Atopic Eczema Using a Non-Invasive Micro-Suction Device in Babies
Innovation PharmaceuticalsMoisturizing lotion
PhilipsPSO-CT02 device
Oregon TherapeuticsSunflower oil
Human BioSciencesStudies of Skin Microbes in Healthy People and in People With Skin Conditions

Clinical Trials (14)

Total enrollment: 3,780 patients across 14 trials

Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.

Start: Mar 2022Est. completion: Mar 202415 patients
Phase 4Unknown

Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema Treatment

Start: Sep 2012Est. completion: Aug 2013310 patients
Phase 3Completed
NCT01429701EMSpolymyxin B sulphate + prednisolone + benzocaine + clioquinol

Effectiveness of Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol in Acute and Sub-acute Dermatitis Eczematous

Start: May 2012Est. completion: Aug 201276 patients
Phase 3Completed
NCT00817063GSKalitretinoin

Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema

Start: Jan 2009Est. completion: Apr 2012599 patients
Phase 3Completed

Study to Evaluate the Efficacy and Safety of ZL-3101 in Subjects With Subacute Eczema

Start: Apr 2017Est. completion: Sep 2018290 patients
Phase 2Completed
NCT02517957Integrated BiosciencesFuroic acid loperamide hydrochloride cream

Xia Shi Surgical Treatment for Eczema Multi-center Clinical Research

Start: Aug 2015342 patients
Phase 2Unknown

Persistence of Oral Tolerance to Peanut

Start: May 2011Est. completion: May 2015556 patients
Phase 2Completed
NCT00329784Allergy TherapeuticsPeanut Consumption Group

Promoting Tolerance to Peanut in High-Risk Children

Start: Dec 2006Est. completion: May 2014640 patients
Phase 2Completed
NCT02075632GSKAlclometasone dipropionate cream

Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream

Start: Sep 2006Est. completion: Nov 2006310 patients
Phase 2Completed
NCT07228962Physical SciencesCutaneous Biomarkers in Atopic Eczema Using a Non-Invasive Micro-Suction Device in Babies

Cutaneous Biomarkers in Atopic Eczema Using a Non-Invasive Micro-Suction Device in Babies

Start: Mar 2026Est. completion: Jun 202730 patients
N/ANot Yet Recruiting

Clinical Evaluation of a Soothing Moisturizing Lotion in Individuals With Atopic Eczema

Start: Feb 2026Est. completion: May 202615 patients
N/ARecruiting
NCT02002871PhilipsPSO-CT02 device

Blue Light for Treating Eczema

Start: Oct 2013Est. completion: Mar 201421 patients
N/ACompleted

Feasibility Study of Barrier Enhancement for Eczema Prevention

Start: May 2010Est. completion: Sep 201246 patients
N/AUnknown
NCT00605878Human BioSciencesStudies of Skin Microbes in Healthy People and in People With Skin Conditions

Studies of Skin Microbes in Healthy People and in People With Skin Conditions

Start: Jan 2008530 patients
N/ARecruiting

Related Jobs in Immunology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 3,780 patients
15 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.